Millipore Sigma Vibrant Logo

AB9078 Anti-Ryanodine Receptor 1 Antibody

View Products on Sigmaaldrich.com
AB9078
100 µL  
가격 검색...
가격을 검색할 수 없습니다
Minimum Quantity needs to be mulitiple of
Maximum Quantity is
가격 문의 추가 정보
()이 할인됨
 
가격 문의
현재 재고 없음
현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      특별 제공

       

      고객 서비스로 문의

      개요

      Replacement Information

      주요 사양표

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, RICC, IHC, WBRbSerumPolyclonal Antibody
      Description
      Catalogue NumberAB9078
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Ryanodine Receptor 1 Antibody
      References
      Product Information
      FormatSerum
      HS Code3002 15 90
      Control
      • Western blot = adult mouse skeletal muscle (adult mouse cardiac muscle will be negative).

        IHC = adult mouse cerebellum Purkinje cells (adult mouse cerebellum granular cells will be negative).
      PresentationRabbit serum. Liquid.
      Quality LevelMQ100
      Applications
      ApplicationAnti-Ryanodine Receptor 1 Antibody detects level of Ryanodine Receptor 1 & has been published & validated for use in IC, IH & WB.
      Key Applications
      • Immunocytochemistry
      • Immunohistochemistry
      • Western Blotting
      Application NotesWestern blot: 1:1,000 using ECL. The antibody reacts with the 500 kDa Ryanodine Receptor 1 protein. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Preferred gel percentage is 4-12% gradient gel.

      Immunocytochemistry: 1:1,000

      Immunohistochemistry: 1:1,000 overnight at 2-8°C using a fluorescently labeled secondary antibody. Suggested fixative is 4% paraformaldehyde in 0.1M PBS (one hour). Suggested permeablization method is 0.05% Triton X-100 in dilution buffer. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS.

      Optimal working dilutions must be determined by the end user.
      Biological Information
      ImmunogenSynthetic peptide from the variant TM region of human Ryanodine Receptor 1.
      HostRabbit
      SpecificityRyanodine Receptor 1.
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes a ryanodine receptor found in skeletal muscle. The encoded protein functions as a calcium release channel in the sarcoplasmic reticulum but also serves to connect the sarcoplasmic reticulum and transverse tubule. Mutations in this gene are associated with malignant hyperthermia susceptibility, central core disease, and minicore myopathy with external ophthalmoplegia. Alternatively spliced transcripts encoding different isoforms have been described.
      Gene Symbol
      • RYR1
      • CCO
      • RyR1
      • RYR
      • MHS1
      • RYR-1
      • SKRR
      • MHS
      • RYDR
      • CCD
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P21817 # Communication between transverse-tubules and sarcoplasmic reticulum. Contraction of skeletal muscle is triggered by release of calcium ions from SR following depolarization of T-tubules.
      SIZE: 5038 amino acids; 565176 Da
      SUBUNIT: Homotetramer (Potential).
      SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (Probable).
      TISSUE SPECIFICITY: Skeletal muscle and brain (cerebellum and hippocampus).
      DISEASE: SwissProt: P21817 # Defects in RYR1 are a cause of malignant hyperthermia (MH) [MIM:145600]. MH is an autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the in vitro contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). & Defects in RYR1 are a cause of central core disease of muscle (CCD) [MIM:117000]. CCD is an autosomal dominant congenital myopathy. Both clinical and histological variability is observed, but affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. & Defects in RYR1 are the cause of multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]; also known as multicore myopathy with external ophthalmoplegia or minicore myopathy with external ophthalmoplegia. MMD is a clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease.
      SIMILARITY: SwissProt: P21817 ## Belongs to the ryanodine receptor family. & Contains 3 B30.2/SPRY domains. & Contains 5 MIR domains.
      MISCELLANEOUS: The calcium release channel is modulated by calcium ions, magnesium ions, ATP and calmodulin. & The calcium release channel activity resides in the C-terminal region while the remaining part of the protein constitutes the 'foot' structure spanning the junctional gap between the SR and the T-tubule. It is possible that the foot structure interacts with the cytoplasmic region of the dihydropyridine receptor. & Ryanodine is an alkaloid that binds to the Ca- release channel in junctional SR and modulates its activity.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      AB9078 04053252329005

      Documentation

      Anti-Ryanodine Receptor 1 Antibody MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Anti-Ryanodine Receptor 1 Antibody Certificates of Analysis

      TitleLot Number
      RABBIT ANTI-RYANODINE RECEPTOR 1 POLYCLONAL ANTIBODY - 2382090 2382090
      RABBIT ANTI-RYANODINE RECEPTOR 1 POLYCLONAL ANTIBODY - 2388823 2388823
      RABBIT ANTI-RYANODINE RECEPTOR 1 POLYCLONAL ANTIBODY - 2395655 2395655
      RABBIT ANTI-RYANODINE RECEPTOR 1 - 3202283 3202283
      RABBIT ANTI-RYANODINE RECEPTOR 1 - 3447464 3447464
      RABBIT ANTI-RYANODINE RECEPTOR 1 - 3928050 3928050
      RABBIT ANTI-RYANODINE RECEPTOR 1 -2891090 2891090
      RABBIT ANTI-RYANODINE RECEPTOR 1 POLYCLONAL ANTIBODY 3005365
      RABBIT ANTI-RYANODINE RECEPTOR 1 POLYCLONAL ANTIBODY - 2080829 2080829
      RABBIT ANTI-RYANODINE RECEPTOR 1 POLYCLONAL ANTIBODY - 2211918 2211918

      References

      Reference overviewApplicationPub Med ID
      Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease.
      Braubach, P; Orynbayev, M; Andronache, Z; Hering, T; Landwehrmeyer, GB; Lindenberg, KS; Melzer, W
      The Journal of general physiology  144  393-413  2014

      요약 표시
      25348412 25348412
      Diurnal and nutritional adjustments of intracellular Ca2+ release channels and Ca2+ ATPases associated with restricted feeding schedules in the rat liver.
      Báez-Ruiz, A; Cázares-Gómez, K; Vázquez-Martínez, O; Aguilar-Roblero, R; Díaz-Muñoz, M
      Journal of circadian rhythms  11  8  2013

      요약 표시
      23962056 23962056
      Ryanodine receptors are expressed in epidermal keratinocytes and associated with keratinocyte differentiation and epidermal permeability barrier homeostasis.
      Denda, S; Kumamoto, J; Takei, K; Tsutsumi, M; Aoki, H; Denda, M
      The Journal of investigative dermatology  132  69-75  2012

      요약 표시
      21881589 21881589
      Spaceflight regulates ryanodine receptor subtype 1 in portal vein myocytes in the opposite way of hypertension.
      Dabertrand, F; Porte, Y; Macrez, N; Morel, JL
      Journal of applied physiology (Bethesda, Md. : 1985)  112  471-80  2012

      요약 표시
      22096120 22096120
      Localization and phenotype-specific expression of ryanodine calcium release channels in C57BL6 and DBA/2J mouse strains.
      Huang, W; Xing, W; Ryskamp, DA; Punzo, C; Križaj, D
      Experimental eye research  93  700-9  2011

      요약 표시
      Immunofluorescence21933672 21933672
      Cytoplasmic gamma-actin and tropomodulin isoforms link to the sarcoplasmic reticulum in skeletal muscle fibers.
      Gokhin, DS; Fowler, VM
      The Journal of cell biology  194  105-20  2011

      요약 표시 기사 전문
      21727195 21727195
      Immunohistochemical study of microscopic globular bodies of normal human brain.
      Saori Odagiri,Fumiaki Mori,Kunikazu Tanji,Naohito Kuroda,Koichi Wakabayashi
      Biomedical research (Tokyo, Japan)  32  2011

      요약 표시
      22033303 22033303
      Proteomic study of calpain interacting proteins during skeletal muscle aging.
      C Brulé,E Dargelos,R Diallo,A Listrat,D Béchet,P Cottin,S Poussard
      Biochimie  92  2010

      요약 표시
      20850499 20850499
      A calcium-induced calcium release mechanism supports luteinizing hormone-induced testosterone secretion in mouse Leydig cells.
      Costa, RR; Varanda, WA; Franci, CR
      American journal of physiology. Cell physiology  299  C316-23  2010

      요약 표시
      20519450 20519450
      Widespread occurrence of eosinophilic neuronal cytoplasmic inclusions in an asymptomatic adult: a novel ubiquitin-negative filamentous inclusion.
      Fumiaki Mori,Yasuo Miki,Kunikazu Tanji,Tomomi Kusumi,Hiroshi Kijima,Koichi Wakabayashi
      Neuropathology : official journal of the Japanese Society of Neuropathology  30  2010

      요약 표시
      20337949 20337949

      관련 제품 및 어플리케이션

      Related Products

      카탈로그 번호 설명  
      MAB3086 Anti-Ryanodine Receptor Antibody, clone RYR.1 가격 및 재고 조회

      카테고리

      Life Science Research > Antibodies and Assays > Primary Antibodies